Vanguard Capital Management
CRSP icon

Vanguard Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Vanguard Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.5M Buy
1,181,847
+39,304
+3% +$2.07M ﹤0.01% 1797
2026
Q1 		$54.4M Buy
+1,142,543
New +$60.3M ﹤0.01% 1815

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management's CRSP Position: Q2 2026 in Review

Vanguard Capital Management increased its CRISPR Therapeutics (CRSP) stake by 3.4% in Q2 2026, buying an estimated $2.07M and bringing the position to 1,181,847 shares worth $64.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1797.

Vanguard Capital Management first reported a position in CRSP in Q1 2026 and has held it in 2 quarters since. 519 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Vanguard Capital Management held 1,181,847 shares of CRISPR Therapeutics worth $64.5M as of Q2 2026.
  • Vanguard Capital Management bought 39,304 CRISPR Therapeutics shares in Q2 2026, an estimated $2.07M.
  • CRISPR Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1797 holding.
  • Vanguard Capital Management first reported a position in CRISPR Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 519 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.